STAAR Surgical's board has authorized a share repurchase program of up to $50M of its outstanding common stock. The program is expected to run for 12 months. STAAR plans to fund repurchases with organic free cash flow and cash on hand, with no outstanding debt and $181.5M in cash, equivalents, and investments as of July 3, 2026. The company had roughly 50.1M shares outstanding as of August 7, 2026, making the authorized buyback equivalent to up to roughly 5% of shares outstanding if fully utilized.
STAAR Surgical CompanyBoard authorized a $50M share buyback, funded by cash and free cash flow, equal to roughly 5% of shares outstanding.
